| Literature DB >> 34070222 |
Huei-Tzu Chien1,2, Chi-Chin Yeh3,4,5, Chi-Kuang Young6, Tzu-Ping Chen7, Chun-Ta Liao8,9, Hung-Ming Wang9,10, Kai-Lun Cho8, Shiang-Fu Huang8,9,11.
Abstract
Head and neck cancer was closely related with habitual use of cigarette and alcohol. Those cancer patients are susceptible to develop multiple primary tumors (MPTs). In this study, we utilized the single nucleotide polymorphisms (SNPs) array (Affymetrix Axion Genome-Wide TWB 2.0 Array Plate) to investigate patients' risks of developing multiple primary cancers. We recruited 712 male head and neck cancer patients between Mar 1996 and Feb 2017. Two hundred and eighty-six patients (40.2%) had MPTs and 426 (59.8%) had single cancer. Four hundred and twelve normal controls were also recruited. A list of seventeen factors was extracted and ten factors were demonstrated to increase the risks of multiple primary cancers (alcohol drinking, rs118169127, rs149089400, rs76367287, rs61401220, rs141057871, rs7129229, older age, rs3760265, rs9554264; all were p value < 0.05). Polygenic scoring model was built and the area under curve to predict the risk developing MPTs is 0.906. Alcohol drinking, among the seventeen factors, was the most important risk factor to develop MPT in upper aerodigestive tract (OR: 7.071, 95% C.I.: 2.134-23.434). For those with high score in polygenic model, routine screening of upper digestive tract including laryngoscope and esophagoscope is suggested to detect new primaries early.Entities:
Keywords: SNP array; head and neck cancer; multiple primary cancer; single nucleotide polymorphism; upper aerodigestive tract
Year: 2021 PMID: 34070222 PMCID: PMC8158753 DOI: 10.3390/jpm11050425
Source DB: PubMed Journal: J Pers Med ISSN: 2075-4426
The demographic data in the cohort of primary and multiple primary tumors for SNP array study (n = 712).
| Characteristics | Cancer Patients [ | Normal Patients [ | |
|---|---|---|---|
| Age (±S.D.) | 52.58 (±10.92) | 43.66 (±15.67) | |
| Range | 25–88 | 18–99 | |
| Tumor subsites | |||
| Oral cavity cancer | 364 (51.1) | ||
| Oropharynx | 135 (19.0) | ||
| Hypopharynx | 190 (29.7) | ||
| Larynx | 14 (0.2) | ||
| Nasal cavity | 2 (0.3) | ||
| Skin | 1 (0.1) | ||
| Esophagus | 6 (0.8) | ||
| Gender | |||
| Male | 707 (99.3) | 398 (100.0) | 0.168 * |
| Female 1 | 5 (0.7) | 0 (0) | |
| Alcohol drinking | |||
| Yes | 481(79.9) | 264 (66.3) | <0.001 |
| No | 121(20.1) | 134 (33.7) | |
| AQ chewing | |||
| Yes | 498 (82.6) | 82 (20.6) | <0.001 |
| No | 105 (17.4) | 316 (79.4) | |
| Cigarette smoking | |||
| Yes | 549 (91.0) | 228 (57.3) | <0.001 |
| No | 54 (9.0) | 170 (42.7) | |
| Number of malignances | |||
| Single primary | 426 (59.8) | ||
| Multiple primary tumors | 286 (40.2) | ||
| Multiple oral cavity cancers | 111 (38.8) | ||
| Multiple upper aerodigestive tract MPTs | 120 (42.0) | ||
| Non-oral and non-aerodigestive tract MPTs | 55 (19.2) |
1 Female patients were excluded in analysis. *: Fisher’s exact test.
The frequency of susceptible SNP locus in patients.
| CHR | SNP | Minor Allele | Frequency | Frequency | Major Allele | Frequency |
|---|---|---|---|---|---|---|
| 1 | rs118169127 | C | 0.088 | 0.02181 | T | 0.06675 |
| 2 | rs112433986 | - | 0.024 | 0.0755 | A | 0.08629 |
| 5 | rs848 | A | 0.4355 | 0.3138 | C | 0.2834 |
| 6 | rs79454125 | C | 0.024 | 0.07191 | T | 0.04672 |
| 6 | rs9490776 | A | 0.02846 | 0.09532 | G | 0.1083 |
| 7 | rs76367287 | C | 0.124 | 0.04849 | A | 0.09068 |
| 9 | rs141057871 | A | 0.2195 | 0.1221 | G | 0.1322 |
| 9 | rs7847271 | A | 0.04 | 0.1271 | G | 0.07305 |
| 10 | rs11255400 | A | 0.028 | 0.08361 | G | 0.03526 |
| 11 | rs12797844 | C | 0.02016 | 0.06376 | T | 0.02519 |
| 11 | rs7129229 | T | 0.2358 | 0.1421 | A | 0.1344 |
| 13 | rs9554264 | T | 0.348 | 0.2258 | C | 0.306 |
| 14 | rs1959792 | T | 0.2621 | 0.151 | C | 0.1679 |
| 16 | rs61401220 | - | 0.108 | 0.04348 | T | 0.03914 |
| 17 | rs9897457 | C | 0.148 | 0.2559 | T | 0.1856 |
| 17 | rs3760265 | T | 0.188 | 0.09866 | C | 0.154 |
| 19 | Affx-15929578 (rs28933396) | A | 0.03361 | 0.1747 | G | 0 |
| 23 | rs149089400 | A | 0.08 | 0.01974 | G | 0.01741 |
Logistic regression of the candidate genes in predicting the risks for formation of multiple primary cancers.
| Name | β | Hazard Ratio | |
|---|---|---|---|
| Alcohol drinking | 1.956 | 0.001 | 7.071 (2.134–23.434) |
| rs118169127 | 1.671 | 0.003 | 5.320 (1.785–15.854) |
| rs149089400 | 1.165 | 0.036 | 3.206 (1.082–9.500) |
| rs76367287 | 1.139 | 0.016 | 3.123 (1.239–7.874) |
| rs61401220 | 1.137 | 0.017 | 3.117 (1.227–7.921) |
| rs141057871 | 1.098 | 0.002 | 2.998 (1.482–6.062) |
| rs7129229 | 0.849 | 0.016 | 2.336 (1.170–4.665) |
| Age ≥ 50 years old | 0.834 | 0.029 | 2.302 (1.088–4.868) |
| rs3760265 | 0.728 | 0.053 | 2.071 (0.990–4.332) |
| rs9554264 | 0.618 | 0.029 | 1.856 (1.066–3.230) |
| rs9897457 | −0.862 | 0.010 | 0.422 (0.220–0.812) |
| rs12797844 | −1.437 | 0.048 | 0.238 (0.057–0.985) |
| rs7847271 | −1.529 | 0.004 | 0.217 (0.077–0.610) |
| rs79454125 | −1.566 | 0.034 | 0.209 (0.049–0.886) |
| rs112433986 | −1.570 | 0.030 | 0.208 (0.050–0.858) |
| rs28933396 | −1.795 | 0.001 | 0.166 (0.056–0.496) |
| rs9490776 | −2.617 | 0.001 | 0.073 (0.016–0.332) |
β: log—hazard ratio.
Figure 1Hazard ratio to develop multiple aerodigestive tract cancer in oral cancer patients. (Red: increased risk; blue dot: decrease risk). The hazard ratio is represented by the size of the dot.
Figure 2ROC curves calculating the best-fit number of genes in predicting multiple aerodigestive tract cancer in oral cancer patients.
The best number of factors predicting the development of multiple aerodigestive tract cancers.
| Positive if Greater than or Equal to | Sensitivity | 1—Specificity | Specificity | Youden Index |
|---|---|---|---|---|
| −7.655000 | 1.000 | 1.000 | 0.000 | 0.000 |
| −6.304500 | 1.000 | 0.996 | 0.004 | 0.004 |
| −5.194500 | 1.000 | 0.988 | 0.012 | 0.012 |
| −4.094000 | 1.000 | 0.967 | 0.033 | 0.033 |
| −3.065500 | 1.000 | 0.902 | 0.098 | 0.098 |
| −2.113000 | 1.000 | 0.853 | 0.147 | 0.147 |
| −1.190000 | 1.000 | 0.763 | 0.237 | 0.237 |
| −0.100500 | 1.000 | 0.653 | 0.347 | 0.347 |
| 0.106000 | 0.989 | 0.584 | 0.416 | 0.405 |
| 1.101500 | 0.955 | 0.380 | 0.620 | 0.575 |
| 2.100000 | 0.865 | 0.241 | 0.759 | 0.624 |
| 2.353000 | 0.843 | 0.208 | 0.792 | 0.635 |
| 2.364500 | 0.843 | 0.204 | 0.796 | 0.639 |
| 2.390500 | 0.843 | 0.200 | 0.800 | 0.643 |
| 2.426500 | 0.843 | 0.196 | 0.804 | 0.647 |
| 2.486500 | 0.831 | 0.196 | 0.804 | 0.636 |
| 2.539500 | 0.831 | 0.192 | 0.808 | 0.640 |
| 2.560000 | 0.809 | 0.188 | 0.812 | 0.621 |
| 3.046500 | 0.742 | 0.122 | 0.878 | 0.619 |
| 4.092000 | 0.438 | 0.033 | 0.967 | 0.406 |
| 5.108500 | 0.213 | 0.000 | 1.000 | 0.213 |
| 6.067000 | 0.090 | 0.000 | 1.000 | 0.090 |
| 8.356000 | 0.011 | 0.000 | 1.000 | 0.011 |
| 9.973000 | 0.000 | 0.000 | 1.000 | 0.000 |
The corresponding genes for selected SNP loci.
| CHR | SNP | A1 | A2 | MAF | Position | ENST No. | Genes | |
|---|---|---|---|---|---|---|---|---|
| 1 | rs118169127 | C | T | 0.05116 | p13.2 | ENST00000369732 | OVGP1//oviductal glycoprotein 1 | Downstream |
| 2 | rs112433986 | - | A | 0.06891 | q35 | ENST00000273067 | MARCH4//membrane associated ring finger 4 | Intron |
| 5 | rs848 | A | C | 0.3199 | q31.1 | ENST00000304506 | IL13//interleukin 13 | UTR-3 |
| 6 | rs79454125 | C | T | 0.06208 | q14.1 | ENST00000306270 | IBTK//inhibitor of Bruton agammaglobulinemia tyrosine kinase | Upstream |
| 6 | rs9490776 | A | G | 0.08999 | q22.31 | ENST00000334268 | TRDN//triadin | Intron |
| 7 | rs76367287 | C | A | 0.07755 | q36.3 | ENST00000444158 | uncharacterized LOC101927914 | |
| 9 | rs141057871 | A | G | 0.1576 | p22.3 | ENST00000422223 | FREM1//FRAS1 related extracellular matrix 1 | Upstream |
| 9 | rs7847271 | A | G | 0.09111 | q33.1 | ENST00000341037 | TNC//tenascin C | Intron |
| 10 | rs11255400 | A | G | 0.05518 | p14 | ENST00000344293 | TAF3//TATA box binding protein associated factor 3 | Intron |
| 11 | rs12797844 | C | T | 0.03587 | q13.3 | ENST00000253925 | PPFIA1//protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1 | Upstream |
| 11 | rs7129229 | T | A | 0.1602 | q14.3 | ENST00000409404 | FAT3//FAT atypical cadherin 3 | Intron |
| 13 | rs9554264 | T | C | 0.2733 | q12.2 | ENST00000241453 | FLT3//fms-related tyrosine kinase 3 | Upstream |
| 14 | rs1959792 | T | C | 0.1858 | q12 | ENST00000546412 | STXBP6//syntaxin binding protein 6 (amisyn) | Upstream intron |
| 16 | rs61401220 | - | T | 0.05045 | q12.1 | ENST00000563826 | LOC101927334 | |
| 17 | rs9897457 | C | T | 0.2128 | p13.1 | ENST00000330767 | TMEM95//transmembrane protein 95 | Downstream |
| 17 | rs3760265 | T | C | 0.1295 | q24.2 | ENST00000533854 | CACNG5//calcium channel, voltage-dependent, gamma subunit 5 | Intron |
| 19 | rs28933396 | A | G | 0.04921 | q13.2 | ENST00000355481 | RYR1//ryanodine receptor 1 (skeletal) | Missense |
| 23 | rs149089400 | A | G | 0.0293 | q27.3 | ENST00000423667 | SPANXN2//SPANX family, member N2 | Upstream intron |
MAF: Minor allele frequency.